Erin Henry, NP
Family · Lawrenceville, GANPI 1407470891
Payments from drug & device makers
Across 723 payments — averaging $186.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$88K
- Tandem Diabetes Care, Inc.$14K
- Sanofi-aventis U.S. LLC$12K
- Dexcom, Inc.$10K
- Novo Nordisk$2K
- Corcept Therapeutics$1K
- plus $8K from 39 others
What the payments were for
- Consulting fees$1,7121%
- Speaking & faculty fees$115,57086%
- Travel & lodging$2,0151%
- Food & beverage$15,54612%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$87,438
- t:slim X2 Insulin Pump with Control-IQ$13,845
- TZIELD$10,685
- DEXCOM G7 GSS (161)$8,585
- DEXCOM STELO GLUCOSE BIOSENSOR$8,585
- Korlym$790
- FREESTYLE LIBRE 3$428
- Ozempic$344
- INPEN SMART INSULIN DELIVERY SYSTEM$273
- TWIIST$262
- Wegovy$229
- DEXCOM G6 TRANSMITTER$225
- t-slim insulin pump$145
- Minimed 670G System$142
- TEPEZZA$134
- MINIMED 780G$133
- EVENITY$133
- Qutenza$130
- AFREZZA$129
- RYBELSUS$114
How this compares
$135,106 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 419 | $737,197 |
| MounjaroTirzepatide | 501 | $697,035 |
| JardianceEmpagliflozin | 163 | $245,243 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 98 | $155,782 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $136,533 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 95 | $123,488 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $113,108 |
| TrulicityDulaglutide | 79 | $112,756 |
| FarxigaDapagliflozin Propanediol | 86 | $112,508 |
| RybelsusSemaglutide | 25 | $56,099 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $45,163 |
| JanuviaSitagliptin Phosphate | 34 | $44,653 |
| Novolog FlexpenInsulin Aspart | 97 | $41,847 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $38,619 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $35,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $2,130 | $836,055514 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,008 | $831,994639 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $115 | $307,059214 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $12,028 | $158,954119 claims |
| AstraZenecaFarxiga | $377 | $112,50886 claims |
| AbbVieSynthroid | $307 | $3,29639 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $117 | $2,312226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Lawrenceville
- Tonita WashingtonLawrenceville$153K
- Jennifer BlackLawrenceville$19K
- Ashley BeikmannLawrenceville$16K
- Allie McAllisterMarietta$299K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.